metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive
mGC or mGEJC - L1 - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 negative
mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
versus irinotecan
	avelumab alone vs. irinotecan	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive
mGC or mGEJC - M - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 negative
versus Standard of Care (SoC)
	avelumab alone vs. Standard of Care (SoC)	1	-410 [-1155; 335] /10000 185/249 vs. 196/250	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
mGC or mGEJC - M - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
	avelumab alone vs. Standard of Care (SoC)	1	83 [-2510; 2677] /10000 19/30 vs. 15/24	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-